Patents Examined by Gary B. Nickol
  • Targeted mutant interferon-beta and uses thereof
    Patent number: 11236141
    Abstract: The present invention relates, in part, to chimeric proteins comprising mutant interferon-? and their use as therapeutic agents.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: February 1, 2022
    Assignees: Orionis Biosciences BV, VIB VZW, Universiteit Gent
    Inventors: Nikolai Kley, Jan Tavernier, Frank Peelman
  • Methods of treatment using an interferon gamma inhibitor
    Patent number: 11230597
    Abstract: The invention encompasses methods of treatment of interferon gamma (IFN-?)-mediated diseases using IFN-? inhibitors, such as anti-huIFN-? antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-? inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-? antibody.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 25, 2022
    Assignee: AMGEN INC.
    Inventors: Andrew A. Welcher, Michael J. Boedigheimer, James B. Chung
  • Anti-galactofuranose antibodies for detecting and treating aspergillosis
    Patent number: 11230594
    Abstract: It is provided novel anti-galactofuranose antibodies and their use for diagnosis of and/or treating aspergillosis, and for the design of chimeric antigen receptor T-cells, wherein single chain variable fragment of the antibodies, such as a heavy chain variable region or a light chain variable region, is fused via a spacer and a transmembrane domain to a signaling endodomain to generate an expression cassette that will be integrated into a T cell.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 25, 2022
    Assignees: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, THE GOVERNORS OF THE UNIVERSITY OF ALBERTA
    Inventors: Donald Christopher Sheppard, Benjamin Alfred William Rufus Ralph, Todd Lambert Lowary, Susmita Sarkar, Amira Ibrahim Aly Mohamed Khalil
  • Yeast strains producing mammalian-like complex n-glycans
    Patent number: 11225646
    Abstract: Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.
    Type: Grant
    Filed: April 11, 2019
    Date of Patent: January 18, 2022
    Assignee: Oxyrane UK Limited
    Inventors: Steven Christian Jozef Geysens, Wouter Vervecken
  • Compositions and methods related to antibodies that neutralize coagulase activity during disease
    Patent number: 11214600
    Abstract: Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 4, 2022
    Assignees: The University of Chicago, Janssen Pharmaceuticals, Inc.
    Inventors: Dominique Missiakas, Olaf Schneewind, Carla Emolo, Lena Thomer, Molly McAdow, Jeroen Geurtsen, Mark De Been
  • Hypolipidemic effects of
    Patent number: 11213553
    Abstract: Disclosed is the hypolipidemic potential of Bacillus coagulans. More specifically the invention discloses the cholesterol lowering potential of Bacillus coagulans MTCC 5856 and therapeutic/biological indications thereof.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: January 4, 2022
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Sivakumar Arumugam, Furqan Ali, Shaheen Majeed
  • GM-CSF variants and methods of use
    Patent number: 11208450
    Abstract: GM-CSF variants, polynucleotides encoding them, and methods of making and using the foregoing are useful in treatment of immune-related disorders, such as inflammatory bowel disease (IBD).
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: December 28, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Thomas Rutkoski, Alexey Teplyakov, Nicole Wunderler
  • Stabilized preparation of interferon beta variant
    Patent number: 11207411
    Abstract: The present invention relates to a stabilized pharmaceutical preparation of R27T, the preparation comprising a human interferon beta variant (R27T), an acetate buffer, arginine, trehalose, Poloxamer 188, and methionine. The stabilized R27T pharmaceutical preparation according to the present invention is obtained by the development of a preparation having a novel composition through the substitution of mannitol with trehalose in the composition of a preparation containing mannitol, which was previously studied by the present inventors.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 28, 2021
    Assignee: ABION INC.
    Inventors: Heejung Lee, Nam Ah Kim
  • Proteins for the treatment of epithelial barrier function disorders
    Patent number: 11207376
    Abstract: The disclosure relates to therapeutic proteins and pharmaceutical compositions comprising said proteins, which have utility in treating various human diseases. In particular aspects, the disclosed therapeutic proteins are useful for treating human gastrointestinal inflammatory diseases and gastrointestinal conditions associated with decreased epithelial cell barrier function or integrity. Further, the disclosed therapeutic proteins are useful for treating human inflammatory bowel disease, including inter alia, Crohn's disease and ulcerative colitis.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: December 28, 2021
    Assignee: Second Genome, Inc.
    Inventors: Andrew Wonhee Han, Andrew Whitman Goodyear, Tarunmeet Gujral, Todd Zachary Desantis, Karim Dabbagh, Toshihiko Takeuchi, Ye Jin, Michi Izumi Willcoxon, Stefanie Banas
  • Assessing susceptibility to cardiac intervention, susceptibility to therapy for heart failure, risk of mortality or further cardiovascular events, and risk of subsequent pulmonary embolism in relevant patients based on determinations of GDF-15, natriuretic peptide, cardiac troponin or combinations thereof
    Patent number: 11199552
    Abstract: The present invention relates to a method of identifying a subject being susceptible to a cardiac intervention based on the determination of GDF-15 in a sample of a subject in need of a cardiac intervention. Moreover, the present invention pertains to a method for predicting the risk of mortality or a further acute cardiovascular event for a subject suffering from a cardiovascular complication based on the determination of GDF-15 and a natriuretic peptide and/or a cardiac troponin in a sample the said subject. Also encompassed by the present invention are devices and kits for carrying out the aforementioned methods.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: December 14, 2021
    Assignee: MEDIZINISCHEN HOCHSCHULE HANNOVER
    Inventors: Kai C. Wollert, Tibor Kempf, Lars Wallentin, Helmut Drexler
  • Variant type III interferons and synthekines
    Patent number: 11198717
    Abstract: Compositions and methods are provided relating to Type III interferons.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: December 14, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Juan Luis Mendoza, Kenan Christopher Garcia
  • Fusion proteins and combination vaccines comprising Protein E and Pilin A
    Patent number: 11198707
    Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.
    Type: Grant
    Filed: July 7, 2020
    Date of Patent: December 14, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Normand Blais, Steve Labbe, Jan Poolman
  • TGFbeta 2 antibodies
    Patent number: 11180546
    Abstract: This invention is in the field of anti-transforming growth factor beta 2 (TGF-?2) antibodies. In particular, the invention provides human monoclonal antibodies that bind the human TGF-?2 isoform preferentially over the human TGF-?1 or TGF-?3 isoforms.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: November 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Chikwendu Ibebunjo, Carsten Jacobi, Angelika Meyer, Eveline Schaadt, Anne-Ulrike Trendelenburg, Olga Vladimirovna Mitina
  • Vaccine for protection against
    Patent number: 11167021
    Abstract: The present invention pertains to a vaccine comprising an IgM protease antigen of Streptococcus suis, for use in a method for protecting piglets having maternally derived anti-Streptococcus suis antibodies against Streptococcus suis, by administering the vaccine to the piglets at an age of at most 28 days, preferably before the piglets are weaned.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: November 9, 2021
    Assignee: Intervet Inc.
    Inventor: Antonius Arnoldus Christiaan Jacobs
  • Anti-CD47 monoclonal antibody and use thereof
    Patent number: 11155632
    Abstract: An anti-CD47 monoclonal antibody and use thereof. The provided anti-CD47 monoclonal antibody can effectively inhibit tumor growth. Blocking human SIRP and human CD47 signals may enhance macrophage phagocytosis of tumor cells, prevent the tumor cells from escaping a tumor immune defense system, and have an anti-tumor function. Blocking association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface may block a “do not eat me” signal from the tumor cells, promoting tumor cell recognition and uptake of macrophages, and thereby facilitating tumor cells to be phagocytosed. The association between the CD47 on a tumor cell surface and the SIRP on a macrophage surface is a common “do not eat me” signal. The anti-CD47 antibody, as a very promising target in the tumor immune system, will play a powerful and effective role in human cancer therapy.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: October 26, 2021
    Assignee: CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD.
    Inventors: Xiao Feng, Lei Jin, Liang Xiao, Tao Wang, Suofu Qin
  • CRISPR-CAS system for a lipolytic yeast host cell
    Patent number: 11149288
    Abstract: The present invention relates to the field of molecular biology and cell biology. More specifically, the present invention relates to a CRISPR-CAS system for a lipolytic yeast host cell.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: October 19, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: Bernard Meijrink, René Verwaal, Bianca Elisabeth Maria Gielesen, Johannes Andries Roubos
  • Methods of treatment of infections using bacteria
    Patent number: 11147844
    Abstract: The present disclosure relates generally to compositions, dosage forms, and methods for preventing and treating infections. The compositions include intact and substantially non-viable Gram-negative bacterial cells which have been treated to reduce lipopolysaccharide (LPS)-associated endotoxin activity, which surprisingly have increased activity to trigger immune cell production of cytokines.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: October 19, 2021
    Assignee: Decoy Biosystems, Inc.
    Inventor: Michael J. Newman
  • virulence factor compositions
    Patent number: 11141473
    Abstract: A multivalent immunogenic composition is provided, including one or more recombinant proteins selected from the group consisting of a recombinant attenuated Staphylococcus pseudintermedius Protein A (SEQ ID NO:2), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin S (SEQ ID NO:4), a recombinant attenuated Staphylococcus pseudintermedius Nucleotidase adenosine synthase protein (AdsA) (SEQ ID NO:6), a recombinant attenuated Staphylococcus pseudintermedius coagulase (SEQ ID NO:8), a recombinant attenuated Staphylococcus pseudintermedius Leukotoxin F (SEQ ID NO: 10), and a recombinant attenuated Staphylococcus pseudintermedius exotoxin 15 (SEQ ID NO: 12). Synthetic genes expressing the attenuated recombinant proteins and optimized for expression in E. coli are provided. Vaccines and therapeutic compositions comprising the one or more recombinant proteins are provided.
    Type: Grant
    Filed: August 10, 2018
    Date of Patent: October 12, 2021
    Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Stephen A. Kania, David Bemis, Mohamed A. Abouelkhair
  • Selectively altering microbiota for immune modulation
    Patent number: 11141481
    Abstract: The invention relates to methods of modulating immune cells in a patient by altering microbiota of the patient. The invention also relates to methods of modulating treatments or therapies in a subject organism by altering microbiota of the subject. The invention also relates to cell populations, systems, arrays, cells, RNA, kits and other means for effecting this. In an example, advantageously selective targeting of a particular species in a human gut microbiota using guided nucleic acid modification is carried out to effect the alteration.
    Type: Grant
    Filed: August 27, 2020
    Date of Patent: October 12, 2021
    Assignee: SNIPR Technologies Limited
    Inventor: Jasper Clube
  • Protein against fungal pathogens
    Patent number: 11142552
    Abstract: The present invention relates to a novel protein comprising novel genes that is extracted from Burkholderia gladioli strain NGJ1. A nucleotide sequence encoding the novel protein is represented by sequence SEQ ID No. 1 and amino acid sequence of the novel protein is represented by the sequence SEQ ID No. 2 is further provided. A nucleotide sequence and the amino acid sequence are obtained from genetically engineered Bg_9562 gene. The novel protein as well as encoding gene is adapted for broad spectrum anti-fungal and mycophagous activities.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: October 12, 2021
    Inventors: Durga Madhab Swain, Sunil Kumar Yadav, Gopaljee Jha